论文部分内容阅读
目的:为提高化疗疗效,降低不良反应,改善患者生活质量,对地黄管食通口服液联合化疗和单纯化疗治疗中晚期食管癌患者的疗效、不良反应及对生存质量的影响进行了比较分析。方法:将60例患者随机分成两组:单纯化疗组(对照组)30例,采用PD方案:紫杉醇(PTX)+顺铂(DDP)。地黄管食通口服液联合化疗组(治疗组)30例,化疗方案同对照组,并于每周期化疗第1天开始口服地黄管食通口服液,每次20mL,每日3次,直至化疗周期结束。2个周期治疗结束后对两组患者的近期疗效、不良反应及生存质量进行评价。结果:地黄管食通口服液组有效率为61.6%,对照组为49.7%,两组比较有显著性差异(P<0.05)。两组化疗后的生存质量差异有显著性(P<0.05)。地黄管食通口服液组的不良反应发生率低于对照组,且发生的程度较轻。结论:地黄管食通口服液联合化疗能提高中晚期食管癌患者化疗的有效率,降低不良反应,改善患者的生存质量。
OBJECTIVE: To compare the curative effect, adverse reactions and quality of life of patients with advanced esophageal cancer treated with Rehmannia glutathione combined with oral chemotherapy and chemotherapy alone in order to improve the curative effect of chemotherapy, reduce the adverse reactions and improve the quality of life of patients. Methods: Sixty patients were randomly divided into two groups: 30 patients in the chemotherapy alone group (control group), PD protocol: paclitaxel (PTX) + cisplatin (DDP). Dihuang Guan Shi Tong oral liquid combined with chemotherapy group (treatment group) 30 cases of chemotherapy with the control group, and in the first day of each cycle of chemotherapy began oral administration of Dihuang Guan Shi Tong oral solution, each 20mL, 3 times daily until the end of the chemotherapy cycle . Two cycles of treatment after the end of the two groups of patients with short-term efficacy, adverse reactions and quality of life were evaluated. Results: The effective rate of Dihuang Guan Shi Tong oral liquid group was 61.6%, while the control group was 49.7%. There was significant difference between the two groups (P <0.05). There was a significant difference in quality of life between the two groups after chemotherapy (P <0.05). Dihuang Guan Shi Tong oral solution adverse reaction rate was lower than the control group, and the occurrence of a lesser extent. Conclusion: Dihuang Guan Shi Tong oral liquid combined with chemotherapy can improve the efficiency of chemotherapy in patients with advanced esophageal cancer, reduce adverse reactions and improve the quality of life of patients.